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Quantitative decision analyses provide a means whereby
the effectiveness, in terms of patient outcome, and costs
of diverse clinical approaches to the care of patients with
cardiovascular disease can be made explicit and under-
standable. Increasingly, the profession is being required
to justify the costs of clinical care to society, government
and third party payers. Such justifications can be effec-
tively presented when structured in decision analytic for-
mat.
To demonstrate the utility of decision analysis and its
extension-rost-effectiveness analysis-as a technique
for presenting the rationale for clinical practices and
technology utilization, the Cardiovascular Norms Com-
mittee of the American College of Cardiology sponsored
a model cost-effectiveness analysis. Alternative manage-
ment options, 6 month mortality and costs for the post-
Radical changes in health care financing are underway. One
major emerging trend is that medicine is becoming more
corporate in structure, so that the influence of nonclinical
decision-makers on the practice of medicine has accelerated.
Guidelines already have been developed in some settings,
dictating the types of care that can be offered a patient.
These guidelines often are based on cost considerations rather
than medical necessity and clinical effectiveness. Of con-
cern is that cost-based guidelines may have a detrimental
impact on both short- and long-term patient outcome (I).
A mechanism is needed whereby information on the fun-
damental contribution of specific cardiovascular procedures
and practices to patient outcome as related to cost can be
marshalled and incorporated into decisions governing their
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myocardial infarction patient were compared. The op-
tions included exercise electrocardiography, exercise
thallium scintigraphy and coronary angiography, fol-
lowed by coronary artery bypass surgery for patients
with left main coronary disease only or patients with left
main disease, three vessel disease or single or double
vessel disease and a significant amount of myocardium
in jeopardy.
Within the constraints of the model, proceeding di-
rectly to angiography for risk stratification was the most
effective approach, lowering expected mortality from
8% to approximately 3%. The marginal costs for this
strategy, however, were high. The most cost-effective
approach was to screen patients initially with exercise
electrocardiography.
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use. lt has been proposed that cost-effectiveness analysis
might provide such a mechanism (2).
Cost-effectiveness analysis and decision-modeling are not
new to medicine and particularly not to issues in cardio-
vascular disease (3-8). Much of the pioneering work trans-
lating quantitative modeling to medical decision-making used
problems in cardiovascular disease, particularly the man-
agement of patients with hypertension and those with coro-
nary artery disease. Demonstration of the utility of a sys-
tematic application of these techniques to cardiovascular
problems by the profession was the goal of this first cost-
effectiveness model undertaken under the auspices of the
American College of Cardiology.
Management of the postmyocardial infarction patient was
the clinical problem chosen to demonstrate the utility of
cost-effectiveness analyses. The underlying rationale was;
1) certain patients who survive a clinically uncomplicated
myocardial infarction remain at high risk for subsequent
cardiovascular morbidity and mortality (9-16); 2) many be-
lieve that certain subgroups of postinfarction patients may
benefit from coronary bypass grafting (17, 18)-however,
there is no generally accepted method by which to select
such subgroups (19); and 3) the management of the post-
infarction patient differs widely among clinicians. Some
073S·I097/87/$3.S0
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clinicians treat patients medically, whereas others perform
one or more of several diagnostic tests in search of the high
risk patient who might benefit from revascularization. The-
oretically, under cost-containment, the more costly tests and
management strategies might be restricted unless efficacy
in terms of patient outcome can be demonstrated.
Methods
This study compared strategies for the management of
the clinically asymptomatic postinfarction patient, involving
combinations of diagnostic tests and indications for surgery
as related to 6 month cardiovascular morbidity, mortality
and costs. The strategies, the level of detail within each
strategy and the probabilities required to perform the anal-
ysis were developed by the Cardiovascular Norms Com-
mittee of the American College of Cardiology. The man-
agement alternatives were not intended to be all inclusive
in this demonstration model. For example, angioplasty as
an alternative revascularization technique was not assessed,
nor was the timing of the interventions (that is, exercise
testing before hospital discharge or at some time during the
recovery phase). The 6 month end point was chosen because
of the availability of data relative to 6 month mortalities.
The Model
Testing procedures. Seven alternative strategies were
compared. These strategies consisted of selected combi-
nations of diagnostic tests and criteria for coronary artery
bypass grafting. The testing procedures considered were
exercise electrocardiography (treadmill). exercise thallium
scintigraphy (thallium scan) and coronary cineangiography.
The results of a treadmill exercise test were considered to
be either strongly positive, otherwise positive. indeterminate
or negative. Strongly positive referred to a treadmill test
during which the patient had both chest pain and evidence
for hemodynamic compromise. An otherwise positive test
referred to one in which angina was produced with or with-
out significant ST segment depression. An indeterminate
test referred to one in which angina was not produced, but
in which ST segment changes were superimposed on an
abnormal baseline electrocardiogram.
The results of a thallium scan were also considered to
be either strongly positive, otherwise positive, indeterminate
or negative. A strongly positive test referred to one in which
hemodynamic compromise occurred in association with a
reversible perfusion defect. Otherwise positive referred to
a test that was positive for a perfusion defect, but without
hemodynamic compromise. An indeterminate thallium scan
referred to scans that could not be interpreted as definitely
showing a reversible defect, but that were abnormal (20,21).
Criteria for coronary bypass grafting. Two criteria for
selecting patients for coronary artery bypass grafting were
considered. Criterion I was to operate only on patients with
left main disease or those patients with a strongly positive
treadmill or thallium scan. Criterion II was to operate on
all patients with a strongly positive treadmill or thallium
scan and patients with left main disease, three vessel disease
or one or two vessel disease, but with a significant amount
of myocardium in jeopardy as predicted from angiography
(22).
Management strategies. Of the seven management
strategies, the first was to manage all patients with standard
medical care, including a beta-adrenergic blocking agent.
None of these patients underwent further diagnostic testing.
The second and third strategies are shown in Figure I.
In this model. all patients undergo a treadmill test, with the
results guiding the subsequent evaluation. Patients having
a strongly positive or otherwise positive treadmill test result
are referred for angiography, and coronary artery bypass
grafting is performed based on surgical Criterion I (Fig. 2).
Patients with a negative treadmill test result are treated with
standard medical care without further diagnostic evaluation.
Patients with an indeterminate treadmill test are referred for
thallium scan. Of the patients referred for thallium scan,
those with a strongly positive, otherwise positive, or in-
determinate thallium scan are referred for angiography, and
coronary artery bypass grafting is performed based on sur-
gical Criterion I (Fig. 2). Patients with a negative scan are
treated with standard medical care. The third strategy is
exactly like the second, except that surgical Criterion II is
used for selecting patients for coronary artery bypass graft-
ing.
The fourth and fifth strategies are shown in Figure 3.
All patients have a thallium scan as the initial test. Patients
with a strongly positive, otherwise positive or indeterminate
scan are referred for angiography (Fig. 2), and coronary
artery bypass grafting is performed based on either surgical
Criterion I (Strategy 4) or Criterion II (Strategy 5). Patients
with a negative scan are managed by standard medical care.
The sixth and seventh strategies are shown in Figure 2.
In these strategies, all patients have coronary angiography,
and coronary artery bypass grafting is performed based on
either surgical Criterion I (Strategy 6) or Criterion II (Strat-
egy 7). For all seven strategies, the outcomes from medical
or surgical therapy assessed in this model are shown in
Figure 4.
This decision problem was evaluated using quantitative
decision analysis. The computations were performed on a
microcomputer using a spreadsheet program.
The Data
Estimates for required data. Estimates for the required
data were derived from review of the pertinent published
literature and from the experience of members of the Car-
diovascular Norms Committee of the American College of
Cardiology. Ranges for each variable also were provided
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Figure 1. Decision tree for Strategies
2 and 3: initial evaluation with tread-
mill exercise electrocardiography
(TME). Exercise thallium scintigra-
phy (THAL) is performed on patients
after an indeterminate treadmill test,
as illustrated in Figure 2. When an-
giography is indicated, the strategy
proceeds as in Figure3. When medical
therapy is indicated, the strategy pro-
ceeds as in Figure 4.
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by the committee members and used in subsequent sensi-
tivity analyses.
Among postinfarction patients, it was estimated that 5%
would have significant left main obstruction, 55% would
have three vessel obstruction, 10% would have one or two
vessel obstruction with significant myocardium in jeopardy
and 30% would have one or two vessel obstruction without
significant myocardium in jeopardy (18,23-26).
Probability of test outcomes. As stated, the exercise
electrocardiogram and the thallium scan each were consid-
ered to generate one of four possible test outcomes: strongly
positive, otherwise positive, indeterminate and negative.
Table I shows the probability of each test outcome that was
estimated for patients with each of the four categories of
anatomic coronary obstruction and myocardium in jeopardy
listed in the preceding paragraph (27-29). In this analysis,
the characteristics of thallium testing were assumed to be
the same when applied to all postinfarction patients as when
applied to patients with an indeterminate treadmill test re-
sult.
The 6 month probability of cardiovascular-related death
after medical therapy for patients with each of the four
categories of anatomic coronary obstruction and myocar-
dium in jeopardy was estimated as follows: for patients with
left main obstruction, 18%; three vessel obstruction, 10%;
one or two vessel obstruction with significant myocardium
in jeopardy, 10%; and one or two vessel obstruction without
significant myocardium in jeopardy, 2% (12,24,28-34).
After coronary arterv bypass grafting, the probability of
cardiovascular-related death in patients with left main coro-
nary artery disease was estimated to be 1.4%, and for each
of the three other categories it was taken to be 1.0% (35).
CABG
Figure 2. Decision tree for Strategies 6 and 7:
initial evaluation withcoronaryangiography. When ANGIOGRAM
medical therapy or coronary artery bypass grafting -----.--""""4.
(CABO) is indicated, strategy proceeds as in Fig-
ure 4.
INOPERABLE
DEATH FROM ANGIOGRAPHY
MEDICAL
MEDICAL
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Figure 3. Decision tree for Strategies 4 and 5: initial evaluation
with exercise thallium scintigraphy (THAL). When angiography
is indicated, the strategy proceeds as in Figure 3. When medical
therapy is indicated, the strategy proceeds as in Figure 4.
In addition, an operative mortality rate of 1.0% was added
(35). Also included was an estimated arteriographic-related
mortality rate of 1.5% for patients with left main coronary
artery obstruction, 0.5% for patients with three vessel ob-
struction or one or two vessel obstruction with significant
myocardium in jeopardy and 0.1 % for patients with one or
two vessel obstruction without significant myocardium in
jeopardy.
The probability of a nonfatal reinfarction also was es-
timated and varied among type of patient and method of
treatment. The probability of a nonfatal reinfarction for pa-
tients treated medically with left main coronary artery ob-
struction, three vessel obsturction and one or two vessel
obstruction with significant myocardium in jeopardy was
estimated at 5% (36). For one or two vessel obstruction and
no significant myocardium in jeopardy, it was estimated at
1% (36). For patients who underwent coronary artery bypass
grafting, the probability of nonfatal reinfarction was esti-
mated to be 6% (37).
Estimated costs. The costs for each strategy were as-
signed as those in excess of the costs of standard medical
care. Estimated costs consisted of standard charges for the
diagnostic tests and cumulative charges for surgery and hos-
pitalization. Specifically, the estimated costs were: treadmill
test, $150; thallium scan, $750; coronary angiography, $2,500;
coronary artery bypass surgery, $15,000; and hospitalization
for nonfatal reinfarction, $1,500. Costs were not discounted
because only a 6 month time period was considered.
Results
Mortality and costs for each strategy. Table 2 shows
the mortality and costs associated with each of the seven
strategies, using the best estimate for each of the input
variables. Mortality refers to the cumulative probability of
death from cardiovascular-related events over a 6 month
period, and includes angiographic-associated mortality and
operative mortality from coronary artery bypass grafting.
Cost per patient refers to the average cost per patient in
excess of the costs associated with standard medical care
for every postinfarction patient who undergoes each partic-
ular strategy. The cost per patient shown for standard med-
ical care is only that incurred by subsequent hospitalization
for a nonfatal infarction. For example, because it was es-
timated that approximately 4% of patients treated medically
would incur a nonfatal infarction, the average cost is 0.04
x $1,500 = $60. For clarity, an illustration of one of the
other strategies follows.
Strategy 3. Treadmill testing. If 100 patients were
managed initially with a treadmill exercise test (Strategy 3),
the total 6 month cost over that associated with standard
medical care would be ($8,970 - $60) times 100, which
would be $891 ,000. Cost per premature death avoided refers
to the cost associated with each strategy that would be ex-
pended for reducing mortality by one life during the 6 month
interval as compared with standard medical care. For ex-
ample, if 100 patients were managed by Strategy 3, there
would be an incremental cost of $891,000, but also a re-
duction in mortality during the 6 months from 8 deaths to
3.9 deaths, for a cost of $217,317 per avoided premature
death. In Table 2, the values for the cost per premature
death will vary slightly from those calculated as just de-
scribed. This is because the values shown in the table for
Figure 4. Outcome of events assessed after medical therapy and
coronary artery bypass grafting (CABG).
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Table I. Probability of the Results of Exercise Treadmill Testing and Thallium Scintigraphy for
Each Category of Anatomic Coronary Obstruction
Site of Coronary Anatomic Obstruction
l.eft Main Three Vessel SMIJ One to Two Vessel
Treadl11111 test result
Strongly positive ()70 0.30 0,20 0.01
Positive o IS 030 0,20 0.05
Indeterminate {J 10 020 0,20 0.20
Negative 005 0.20 040 0.74
Thallium test result
Strongly positive on 060 030 0.01
Positive 0.20 0,25 040 0.19
Indeterminate o.m 0.05 0,10 0,10
Negative o.o: o.t 0 0,20 (UO
SMIJ =, significant amount 01 myocardium in jeopardy.
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mortality and average cost are rounded off. The values shown
in Table 2 for cost per avoided premature death are based
on the original and not rounded off values,
Strategy 7. Angiography plus surgical criterion II.
Table 2 shows that Strategy 7 (initial evaluation with an-
giography and the use of surgical Criterion" as the operative
indication) is associated with the lowest overall mortality
(3,1%), Strategies 5 (exercise thallium scintigraphy) and ~
(treadmill exercise electrocardiography) also lower overall
mortality to <4% (3.5 and 3,9%, respectively). All three
of these strategies are associated with the less stringent
criterion for coronary artery bypass grafting. Each of the
strategies associated with the more stringent criterion for
coronary artery bypass grafting (Criterion I) reduces mor-
tality only minimally from that associated with medical ther-
apy alone,
Also shown inTable 2 is that Strategy ~ (initial evaluation
with a treadmill exercise test) had the lowest cost per pre-
mature death avoided ($217,000), Strategy 7 (initial eval-
uation with angiography) was the second most cost-effective
strategy at $241.510, The marginal cost associated with the
use of Strategy 7 as compared with Strategy 3 is $360,670,
This means that Strategy 7 would be preferred over Strategy
3 only if one is willing to pay $360.670 per premature death
avoided in order to reduce overall mortality from 3.9 to
3.1%.
Sensitivity analyses. After the initial analyses. the effect
of varying the input data on the outcome of each strategy
was evaluated, Figures 5 to 7 illustrate these sensitivity
analyses on four strategies (medical therapy only and the
three strategies associated with surgical Criterion II). Figure
5A shows the effect on the predicted mortality with each
strategy that occurs when the proportion of patients with
one or two vessel obstruction without significant myocar-
dium in jeopardy ranged from 15 to 90%. It can be seen
that the relative ranking of the strategies remained un-
changed as the proportion of left main obstruction was raised
from 2 to 20% (Fig. 5B) and of three vessel obstruction
from 25 to 75% (Fig. 5C).
Standard medical care versus coronary bypass graft-
ing. The effect of changing the estimates of predicted mor-
tality after standard medical care and that of coronary artery
bypass grafting was also evaluated. By varying the 6 month
probability of death with medical therapy through a 50%
Table 2. Mortality and Costs Associated with the Strategies for Managing the Asymptomatic
Patient After Myocardial Infarction
6 Month Average Cost/Premature
Strategies: Probability Cost/Patient Death Avoided
Initial Test-Surgical Criterion of Death ($) ($)
I) Standard Medical Care OO~O 60 Baseline
2) Treadmill-Criterion I 0,075 2,420 496,140
3) Treadmill-Criterion" OOJ9 ~,970 217,000
4) Thallium-Criterion t 0,076 3,260 988,550
5) Thallium-Criterion" Om5 11.030 245,850
6) Angiograrn-Criterion I 0077 3.130 1.167,530
7) Angiogram-Criterion " o,ml 12,020 241.510
Criterion I = bypass surgery for left main coronary artery disease only; Criterion It = bypass surgery for
left main coronary artery disease, three vessel disease or one or two vessel disease and significant myocardium
in jeopardy: Thallium = exercise thallium scintigraphy; Treadmill = treadmill exercise electrocardiography.
10
• '~
II
g
~ 7
:J
e
l- IIII:
0
:I
II: 5j
~ :~'"uWI 4..>0Q 3II:~
-2
A
0
0 20 40 lID 110 100
PERCENTAGE OF ONE OR TWO VESSEL DISEASE
10
•
II Figure 5. Sensitivity analyses on the distribution of
g type of anatomic coronary obstructio n. A, B and C
~ 7 depict changes in predicted mortality with four strat-
:J egies by varying one variable (shown along the hor-e
l- II izontal axis) in each figure. The four strategies shownII:0
:I are Strategy I- medical care , and the three strategies
II: 5s associated with surgical Criterion II: Strategy 3-
~ treadmill test first, Strategy 5- thallium test first andu
WI 4 3 Strategy 7-angiogram first. In A, the percentage ofe
> 50 patients with one or two vessel disease varies fromQ 3 7II: 10 to 90%. In B, the percentage of patients with left~
2 main coronary artery disease varies from 2 to 20%.
In C, the percentage of patients with three vessel
disease varies from 25 to 75%.
B
0
0 4 II 12 III 20 24
PERCENTAGE WITH LEFT WAIN DISEASE
10
•
---II
g
~ 7
:J
~ IIII:
0
:I
II: 5j
~
u
WI 4
--~ 3
2 5
Q 3 7II:
s
2
C
0
0 20 40 110 110 100
PERCEIiTAGE OF THREE VESSEL DISEASE
lACC Vol. 10. No.4
October 1987:869-78
DITIUS ET AL.
COST-EFFECTIVE POSTINFARCTION MANAGEMENT
875
13
12
11
l 10
~
:J 9~
o 8
:I
El 7
l-
•~ 8
~ 5
>-ffi 4
l-
•~ 3
.,
2
3
5
7
121086
NORTAUTY WITH NEOICAL CARE ONLY (_)
-----------~~
~
~
A
o
o
8
9
7
5
2
3
12
11
10
~
:::;
s
II:
o
:I
o
...
l-
•(j
o
UI
.,
•
>-
o
...
~
l-
UI
Figure 6. Sensitivity analyses on the effectiveness
of therapy. A and 8 depict changes in predicted mor-
tality with four strategiesby varyingthe effectiveness
of medical therapy(A) and of coronary artery bypass
surgery (CABO) (8). The fout strategies shown are
Strategy I-medical care, and the three strategies
associated with surgical Criterion II: Strategy 3-
treadmill test first, Strategy 5-thallium test first and
Strategy 7-angiogram first.
o
B
o 8 10 12
NORTAUTY fOLLOWING CABG (_)
increase (overall 12%) to a 50% decrease (overall 4%), the
relative performance of the strategies remains intact (Fig.
6A). As medical therapy improves. however, the cost per
premature death avoided increases sharply, since the ad-
vantage of coronary artery bypass grafting decreases. Stan-
dard medical care only approaches the expected mortality
with all other strategies when the estimate of the mortality
after medical care is lowered by 75%, making the overall
6 month probability of death with medical therapy 2%.
Figure 68 shows the impact of changes in the estimate of
the efficacy of coronary artery bypass grafting on strategy-
associated mortality. Standard medical therapy became
equivalent to the other strategies with respect to mortality
only when the 6 month probability of death after coronary
artery bypass grafting increased IO-fold to 10%.
Although the cost of routine coronary artery bypass sur-
gery was estimated to be $15,000, in some centers this can
be as high as $25,000. Figure 7 shows the cost-effectiveness
of Strategies I, 3, 5 and 7 as the cost of coronary artery
surgery varies. The lower end of these costs would not be
possible with the costs of traditional bypass grafting. The
figure is included to demonstrate the cost-effectiveness of
these strategies if an alternative procedure was developed
that was equally efficacious as bypass grafting, but less
costly.
Discussion
Benefits of cost-effectiveness analyses. This model, de-
veloped under the auspices of the Cardiovascular Norms
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Committee of the American College of Cardiology, is the
first cardiovascular association-sponsored analysis designed
to demonstrate a method whereby the rationale for and the
benefits to be derived from alternative approaches to clinical
cardiologic care can be made explicit. The analysis. which
assesses both effectiveness and costs of alternative strate-
gies, provides a model for decision-making that brings into
balance both medical and cost considerations. Cost-effec-
tiveness analyses have much to offer as a rational and mean-
ingful approach to cost containment. Any method that does
not consider the relations between cost and effectiveness in
terms of patient outcome is certain to result in arbitrary
resource allocations and the potential for more costly than
cost-saving decisions as well as decisions potentially de-
trimental to quality care. It is not difficult. for example. to
envision that in the name of cost containment. coronary
arteriography. risk assessment or revascularization might be
restricted in the postinfarction setting. Demonstrations of
the effectiveness of such interventions in a reduction in
mortality or morbidity need to be available to substantiate
professional claims that such restrictions would infringe on
quality care.
In addition to the socioeconomic and quality care ad-
vocacy values inherent in analyses such as demonstrated in
this model, information also may be a byproduct of im-
portance to medical decision-making. For example. the clin-
ical benefit to be derived from risk stratification of patients
after an uncomplicated myocardial infarction is supported
by this model. Three different management strategies de-
signed to detect high risk subgroups of patients lowered the
predicted6 inonth mortality into secondary to cardiovascular
causes after myocardial infarction from approximately 8%
for all groups of patients if treated conservatively to ap-
proximately 3.5% for the patients undergoing further eval-
uation and revascularization therapy for anatomic findings
thought to represent high risk. The improved predicted mor-
tality resulted primarily from the performance of coronary
artery bypass grafting in those patients with three vessel
disease or those with one or two vessel obstruction, but with
a significant amount of myocardium in jeopardy (38). Op-
erating exclusively on patients with left main coronary artery
disease was not as effective a strategy. lowering predicted
mortality rate to only 7.5%. It should also be noted that the
method of screening for high risk played an important though
less significant role than bypass surgery. Differences in the
expected mortality among the treadmill exercise. thallium
scintigraphy and angiography strategies were modest. rang-
ing from 3. 1 to 3.9%.
The most cost-effective strategy. In this model. the
strategy beginning with treadmill exercise testing was the
most cost-effective and remained so under every condition
imposed by the sensitivity analyses. With the treadmill test-
ing strategy. the 6 month mortality rate could be expected
to decrease on the average from 8.0 to 3.9%. The cost per
avoided premature death was just under $220.000. The mar-
ginal cost for managing patients initially with coronary an-
giography as compared with starting with a treadmill ex-
ercise test was higher (about $360.000). The thallium
scintigraphy strategy also was associated with a higher mar-
ginal cost. It should be noted. however. that in this model,
treadmill and thallium tests essentially were being used only
as screening tests for risk: the decision regarding surgery
or no surgery was based on the patients' anatomic coronary
disease. If the tests are also considered on the basis of their
sensitivity and specificity for the detection of some under-
lying pathophysiologic mechanism for risk (ischemia. for
lACC Vol. 10. No.4
October 19~7:~69~7~
DITTUS ET AL.
COST·EFFECTIVE POSTINFARCTION MANAGEMENT
877
example), their comparative values might become apparent.
For example, a test highly sensitive and specific for isch-
emia, to the extent that prognosis is related to ischemia,
might be less costly, more or equally effective and, thus,
overall more cost-effective than a strategy that would rec-
ommend sending a patient directly to arteriography. This
hypothesis (namely, that a test with the best predictive value
for ischemia would also be the most cost-effective in the
management of the postinfarction patient) is currently being
evaluated.
Sensitivity analyses of the data in the model reveal that,
for conservative medical therapy to be the strategy associ-
ated with the lowest mortality, either the probability of death
within 6 months, on the average, for the patients treated
medically needed to be ::0;2%, or the probability of death
on the average after coronary artery bypass grafting needed
to be >10%.
The major cost associated with all (~I these strategies is
the cost ofperforming surgery: 80% of the total cost of the
strategies is attributable to coronary artery bypass grafting.
This cost so dominates these strategies, that if the cost of
all of the diagnostic tests, including arteriography, were
reduced by 50%, the effect on cost-effectiveness would be
to decrease total costs by only 10%. Conversely, if the cost
of bypass surgery were reduced by 5W'!r, , the impact on cost-
effectiveness would be significant, lowering each strategy's
average cost by 40%. This analysis, therefore, suggests that
for the cost of patient management in this setting to be
substantially reduced, a less expensive revascularization
procedure would be required or the cost of bypass grafting
reduced.
Potential problems of the model. The major potential
problems with this type of decision analysis surround the
structure of the model and the accuracy of the data. Models
only approximate reality. This particular model was de-
signed originally to demonstrate the utility of cost-effec-
tiveness analysis, and the level of detail was not intended
to be exhaustive, nor were the input data subjected to broad-
based validation studies. Future models of the management
of the postinfarction patient, for example, should consider
other tests that might have prognostic value, such as, left
ventricular ejection fraction or other clinical variables. In
addition, instead of restricting the outcome evaluation to
avoided premature death 6 months after myocardial infarc-
tion, a measure of quality-adjusted life over the patient's
subsequent lifetime should be incorporated. Furthermore,
future work should include comparisons between Iiterature-
derived estimates with data available in data banks or with
new data derived from projects designed to collect specific
information. The formation of an ongoing data collection
system relative to major cardiovascular procedures and prac-
tices would be an important advance. Despite the potential
problems with cost-effectiveness analyses, however, the ex-
tensive sensitivity analyses performed in this study do in-
dicate that the basic conclusions would not be altered by
even substantial deviation in the estimates required to per-
form the analyses.
Physicians' resistance to anything that remotely resem-
bles cookbook medicine, as might be derived from such
analyses, should be moderated with the understanding that
cost-effectiveness analyses are, in essence, models of the
"average" patient. the same "average" patient around whom
reimbursement decisions are being made. Models arc not
prescriptive for individual patient management; they are
information packets that may serve as guides to cost-effec-
tive care. For example, if an individual postmyocardial in-
farction patient has, by individual physician assessment. an
expected mortality rate of 2%, it would not be cost-effective
to do risk stratification. Similarly, if a patient had an ex-
pected surgical mortality rate of 6 to 8% for reasons of
concomitant disease or other factors, risk stratification would
not be indicated. Similarly, the sensitivity or specificity of
tests may vary among different institutions, making angi-
ography more cost-effective than treadmill testing or thal-
lium imaging more effective in some settings. These con-
siderations can be incorporated through sensitivity analyses,
thus "customizing" the analysis for the individual patient
and practice setting.
Problems with this analytic approach are not small: thev
include the need for adequate representation of the relevant
clinical concerns and practices within the model structure,
the data-gathering mechanisms and data validity. To meet
the needs of cost-effectiveness analyses, the resources of
industry, medical associations, academic and practice units
and government may need to be pooled.
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